期刊文献+

长链非编码RNA TMEVPG1在原发性免疫性血小板减少症患者预后评估中的价值 被引量:2

Value of long non-coding RNA TMEVPG1 in prognosis evaluation of patients with primary immune thrombocytopenia
下载PDF
导出
摘要 目的探讨长链非编码RNA(lncRNA)TMEVPG1在原发性免疫性血小板减少症(ITP)患者预后评估中的价值。方法选取126例ITP患者作为研究组,根据ITP患者预后情况分为预后不良组31例和预后良好组95例,另选取同期体检的125例健康者作为对照组。采用实时荧光定量PCR(qRT-PCR)测定lncRNA TMEVPG1相对表达量;采用Pearson法分析ITP患者lncRNA TMEVPG1与血小板计数、干扰素-γ(IFN-γ)、白细胞介素(IL)-2、IL-4、IL-10的相关性;采用COX回归分析探讨影响ITP患者预后的有关因素。结果与对照组比较,研究组患者lncRNA TMEVPG1水平降低,差异有统计学意义(P<0.05);预后不良组患者lncRNA TMEVPG1水平低于预后良好组,差异有统计学意义(P<0.05)。lncRNA TMEVPG1与血小板计数、IL-4、IL-10呈正相关,与IFN-γ、IL-2呈负相关(P<0.05);lncRNA TMEVPG1降低是ITP患者预后不良的独立危险因素(P<0.05)。结论LncRNA TMEVPG1水平降低与ITP患者预后不良有关,其可作为ITP患者预后评估的辅助指标。 Objective To investigate the value of long non-coding RNA(lncRNA)TMEVPG1 in the prognosis evaluation of patients with primary immune thrombocytopenia(ITP).Methods A total of 126 ITP patients were selected as the study group.According to the prognosis of ITP patients,they were divided into poor prognosis group(n=31)and good prognosis group(n=95),and 125 healthy subjects who underwent physical examination during the same period were selected as control group.The relative expression level of lncRNA TMEVPG1 was determined by quantitative real-time polymerase chain reaction(qRT-PCR);correlations of lncRNA TMEVPG1 with platelet count,interferon-γ(IFN-γ),interleukin(IL)-2,IL-4 and IL-10 in ITP patients were explored by Pearson correlation;the factors influencing the prognosis of ITP patients were analyzed by COX regression.Results Compared with the control group,lncRNA TMEVPG1 level in the study group was significantly decreased(P<0.05);lncRNA TMEVPG1 level in the poor prognosis group was significantly lower than that in the good prognosis group(P<0.05).LncRNA TMEVPG1 was positively correlated with platelet count,IL-4 and IL-10,and negatively correlated with IFN-γand IL-2(P<0.05).Lower lncRNA TMEVPG1 was an independent risk factor for poor prognosis in ITP patients(P<0.05).Conclusion The decreased level of LncRNA TMEVPG1 is associated with poor prognosis in ITP patients,which can be used as an auxiliary indicator to evaluate the prognosis of ITP patients.
作者 许建红 陈元锋 竺青 刘丽丽 刘虹 谯铭铭 XU Jianhong;CHEN Yuanfeng;ZHU Qing;LIU Lili;LIU Hong;QIAO Mingming(Department of Apheresis,Shandong Blood Center,Jinan,Shandong,250014)
出处 《实用临床医药杂志》 CAS 2023年第3期16-20,共5页 Journal of Clinical Medicine in Practice
基金 山东省医药卫生科技发展计划项目(2019WS540)。
关键词 原发性免疫性血小板减少症 长链非编码RNA TMEVPG1 预后 白细胞介素-2 primary immune thrombocytopenia long non-coding RNA TMEVPG1 prognosis interleukin-2
  • 相关文献

参考文献8

二级参考文献78

  • 1朱小勤,陈珮,邱仲川,黄中迪,赵琳,胡晓莹,瞿玮颖,陆颖佳,封舟.紫癜合剂对原发免疫性血小板减少症患者Treg/Th17细胞平衡的影响[J].上海中医药杂志,2020,54(S01):86-89. 被引量:3
  • 2杨小猛,刘仿,陈群,赵丹,伍昌林,蔡康荣,肖红.特发性血小板减少性紫癜患儿Th1/Th2、Tc1/Tc2亚群漂移的研究[J].中国免疫学杂志,2005,21(1):76-79. 被引量:10
  • 3ProvanD, StasiR, NewlandAC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood,2010,115(2):168-186.
  • 4NeunertC, LimW, CrowtherM, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood,2011,117(16):4190-4207.
  • 5British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy[J]. Br J Haematol,2003,120(4):574-596. doi:10.1046/j.1365-2141.2003.04131.x.
  • 6WeiY, JiXB, WangYW, et al. High-dose dexamethasone versus prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial[J]. Blood,2016,127(3):296-302. doi:10.1182/blood-2015-07-659656.
  • 7WangS, YangR, ZouP, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia[J]. Int J Hematol,2012,96(2):222-228. doi:10.1007/s12185-012-1124-8.
  • 8BusselJB, ChengG, SalehMN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura[J]. N Engl J Med,2007,357(22):2237-2247. doi:10.1056/NEJMoa073275.
  • 9BusselJB, ProvanD, ShamsiT, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, doubleblind, placebo-controlled trial[J]. Lancet,2009,373(9664):641-648. doi:10.1016/S0140-6736(09)60402-5.
  • 10ChengG, SalehMN, MarcherC, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study[J]. Lancet,2011,377(9763):393-402. doi:10.1016/S0140-6736(10)60959-2.

共引文献455

同被引文献25

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部